Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Respir Med. 2020 Dec;175:106210. doi: 10.1016/j.rmed.2020.106210. Epub 2020 Nov 4.
ALI/ARDS is a severe lung injury leading to refractory respiratory failure, accounting for high morbidity and mortality. However, therapeutic approaches are rather limited. Targeting long non-coding RNA MALAT1 and microRNA miR-181a-5p might be potential option for ALI/ARDS intervention.
We aimed to investigate the role of MALAT and miR-181a-5p in the pathogenesis of ALI/ARDS, and test the therapeutic effects of targeting MALAT and miR-181a-5p for ALI/ARDS intervention in vitro.
MALAT1 and miR-181a-5p levels were measured in plasma from ALI/ARDS patients. In vitro human pulmonary microvascular endothelial cell (HPMEC) injury was induced by LPS treatment, and molecular targets of MALAT1 and miR-181a-5p were explored by molecular biology approaches, mainly focusing on cell apoptosis and vascular inflammation. Interaction between MALAT1 and miR-181a-5p was also detected. Finally, the effects of targeting MALAT1 and miR-181a-5p for ALI/ARDS intervention were validated in a rat ALI/ARDS model.
MALAT1 upregulation and miR-181a-5p downregulation were observed in ALI/ARDS patients. Transfection of mimic miR-181a-5p into HPMECs revealed decreased Fas and apoptosis, along with reduced inflammatory factors. Fas was proved to be a direct target of miR-181a-5p. Similar effects were also present upon MALAT1 knockdown. As for the interaction between MALAT1 and miR-181a-5p, MALAT1 knockdown increased miR-181a-5p expression. Knocking down of MALAT1 and miR-181a-5p could both improve the outcome in ALI/ARDS rats.
MALAT1 antagonism or miR-181a-5p could both be potential therapeutic strategies for ALI/ARDS. Mechanistically, miR-181a-5p directly inhibits Fas and apoptosis, along with reduced inflammation. MALAT1 negatively regulates miR-181a-5p.
ALI/ARDS 是一种严重的肺损伤,导致难治性呼吸衰竭,发病率和死亡率都很高。然而,治疗方法相当有限。针对长链非编码 RNA MALAT1 和 microRNA miR-181a-5p 可能是 ALI/ARDS 干预的潜在选择。
我们旨在研究 MALAT 和 miR-181a-5p 在 ALI/ARDS 发病机制中的作用,并测试针对 MALAT 和 miR-181a-5p 治疗 ALI/ARDS 的体外疗效。
测量 ALI/ARDS 患者血浆中的 MALAT1 和 miR-181a-5p 水平。用 LPS 处理体外人肺微血管内皮细胞(HPMEC)损伤,通过分子生物学方法探索 MALAT1 和 miR-181a-5p 的分子靶点,主要集中在细胞凋亡和血管炎症上。还检测了 MALAT1 和 miR-181a-5p 之间的相互作用。最后,在大鼠 ALI/ARDS 模型中验证了针对 MALAT1 和 miR-181a-5p 治疗 ALI/ARDS 的效果。
在 ALI/ARDS 患者中观察到 MALAT1 上调和 miR-181a-5p 下调。转染 mimic miR-181a-5p 到 HPMECs 中发现 Fas 和凋亡减少,同时炎症因子减少。Fas 被证明是 miR-181a-5p 的直接靶标。MALAT1 敲低也有类似的效果。至于 MALAT1 和 miR-181a-5p 之间的相互作用,MALAT1 敲低增加了 miR-181a-5p 的表达。MALAT1 和 miR-181a-5p 的敲低都可以改善 ALI/ARDS 大鼠的预后。
MALAT1 拮抗或 miR-181a-5p 都可能是 ALI/ARDS 的潜在治疗策略。机制上,miR-181a-5p 直接抑制 Fas 和凋亡,同时减少炎症。MALAT1 负调节 miR-181a-5p。